CD79A and infection: The intrinsic biological properties of IgG make this isotype the predominant focus of antibody-based therapeutics, but improvements in half-life and kinetics of other isotypes could lead to therapeutics tailored to the site of infection as would be the case with IgA and respiratory or enteric infections [157].